8 pharmaceutical companies shortlisted for global respected companies in 2019

[China Pharmaceutical network industry news] recently, fortune website released the list of "global respected companies in 2019" It is reported that the list mainly refers to 9 indicators, namely innovation, personnel management, enterprise asset use, social responsibility, management quality, financial stability, long-term investment value, product / service quality and global competitiveness In the pharmaceutical industry, only Johnson & Johnson is in the top 50 In addition to Johnson & Johnson, there are Merck, Roche, Novartis, Amgen, Bristol Myers Squibb, Pfizer and Aberdeen Total score of J & J: 8.08 on January 22, J & J announced its performance in 2018, achieving a total revenue of US $81.582 billion, an increase of 6.7% compared with 2017 The total R & D investment is US $10.775 billion, accounting for 13.2% of revenue, an increase of 1.7% compared with 2017 From the perspective of regional distribution of income, Asia Pacific and Africa are the places where Johnson & Johnson's performance grew rapidly in 2018, with a growth rate of 10.5%, followed by Europe's 9.5% Total score of MSD: 7.46 shares of MSD, a pharmaceutical giant, rose by more than 30% in 2018, the largest annual increase since 2006 A key factor in MSD's outstanding performance was the strong growth in sales of keytruda, a drug used to treat various forms of cancer In the first and second quarters of this year, keytruda's sales surged 150% and 89% year-on-year, respectively, and in the third quarter, sales rose 80% Total score of Roche: 7.09 from Roche's development, it can be seen that Roche, as a younger pharmaceutical enterprise, has rewritten the power layout of pharmaceutical enterprises In the past 20 years, the three carriages driving Roche's growth are innovation, acquisition and advanced R & D vision With the advent of the digital era, the pattern among pharmaceutical enterprises is being rewritten It has been 120 years since Roche's development Throughout Roche's development, innovation is indeed Roche gene But what's more important is that Roche establishes its market position with breakthrough innovation towards unsatisfied demand every time Total score of Novartis: 7.08 from January to September 2018, Novartis achieved an operating revenue of 559 million yuan, a year-on-year increase of 30.09%; the average operating revenue growth rate of individual shares disclosed in the third quarter of the chemical pharmaceutical industry was 37.21%; the net profit attributable to shareholders of listed companies was 64.397 million yuan, a year-on-year increase of 80.91%; the average net profit growth rate of individual shares disclosed in the third quarter of the chemical pharmaceutical industry was 82.42%; The company's earnings per share is 0.49 yuan Amgen's total score: 6.92 in the second fiscal quarter of 2018, Amgen's net profit was $2.296 billion, a year-on-year increase of 6.74%; its operating revenue was $6.059 billion, a year-on-year increase of 4.29% As a pioneer of biotechnology, Amgen has grown into a large independent biotechnology company in the world, has reached millions of patients in the world, and is developing a series of drugs with breakthrough potential Total score of Bristol Myers Squibb: 6.84 on January 24, Bristol Myers Squibb released its financial report for 2018 The total revenue of BMS in the whole year was 22.561 billion US dollars, up 9% compared with 2017 Among them, two heavyweight drugs, opdivo and eliquis, support half of BMS revenue Opdivo achieved revenue of US $6.735 billion and sales growth of 36%, maintaining strong growth for five consecutive years Pfizer's total score: 6.65 on October 30, Pfizer announced its third quarter results, adjusted earnings per share of 78 cents in the third quarter, and market estimates of 75 cents Third quarter revenue was $13.3 billion, with analysts predicting $13.53 billion Net profit in the third quarter was $4.114 billion, compared with $2.84 billion in the same period last year Net profit in the third quarter was a loss of $22.859 billion, compared with $1.694 billion in the same period last year Pfizer expects annual revenue of $53 billion to $53.7 billion Total score of EBV: 6.49 EBV recently released its financial report for 2018, with adjusted net income of US $32.733 billion for the whole year, an increase of 15.2% compared with last year Among them, Humira's global sales in 2018 reached US $19.936 billion, an increase of 7.4% on the basis of operation, including US $13.685 billion in net revenue and international $6.251 billion in net revenue.